Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-158-2 | CAS number: 17091-31-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 03/2008 to 09/2008
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 07072601
- Expiration date of the lot/batch: 26.07.2008
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature 20 ± 5 °C - Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- Wistar-Unilever
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann GmbH, Gartenstraße 27, 33178 Borchen, Germany
- Age at study initiation: 5- 8 weeks
- Weight at study initiation: 141-166 g (females), 163-185 g (males)
- Diet (e.g. ad libitum): Maintenance diet rat/mouse, pellets, No. 1324 (Altromin GmbH & Co. KG, 32791 Lage), ad Jib.
- Water (e.g. ad libitum): Autoclaved community tap water, ad lib.
- Acclimation period: 8 days (males), 9 days (females)
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3°C
- Humidity (%): 30-70%
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The required amount of Bromo(hexahydro-2H -azepin-2-onato-N)magnesium is weighed into an appropriate vial on an analysis scale. Water is added up to the required volume. Stirring for 5 minutes. The test solutions were intended for an application volume of 4 ml per kg body weight. All preparation protocols for the test solutions were stored with the raw data.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
- Dose / conc.:
- 63 mg/kg bw/day (nominal)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control:
- no
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once a week
BODY WEIGHT: Yes
- Time schedule for examinations: Once a week
FOOD EFFICIENCY:
- Group food consumption: Once weekly
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once before application and once during the last exposure week
- Battery of functions tested: grip strength - Sacrifice and pathology:
- HISTOPATHOLOGY: Yes
Gross lesions
Oesophagus
Trachea and thyroid
Stomach
Thymus
Liver
Spleen
Duodenum
Jejunum
Ileum (with peyer's p patches)
Cecum
Colon
Rectum
Lymph nodes (intestinal p area)
Kidney
Adrenals
Urinary bladder
Testes/ovary
Epididymides
Prostata/uterus
Heart
Lungs
Peripheral nerve
Bone marrow
Sternum
Spinal cord
Whole brain
Cerebrum
Cerebellum
Pons - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Observation of apathetic behaviour amongst male animals of the high dose group in the last two days of the in-life phase.
Elevated water consumption for both sexes, especially in the high dose group.
Increased weight gain in the high dose groups.
Increased liver and kidney weights in the male high dose group and increased liver weight in the female high dose group. - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Female animals in the high dose group showed increased weight gain in comparison to the vehicle group.
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Analysis of haematology and serum biochemistry showed normal results in most instances.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Mild effects were observed mainly in the high dose groups.
In the male animals, significant but weak changes in the data of the high dose group
emphasised a lowered creatinine and glutamic-oxaloacetic transaminase (GOT) level, as
well as an elevated level in chloride and cholesterol and a higher mean corpuscular volume
(MCV). In the medium dose group, chloride levels and MCV were also elevated. The low
dose group showed an elevated cholesterol level, as well. These parameters can be
indicators for an alteration of kidney function.
In the female high dose animals, creatinine levels were also lowered, whereas globulin,
chloride, alanine aminotransferase (GPT), and alkaline phosphatase levels were elevated.
Globulin levels were also elevated in the medium dose animals. These parameters can be
indicators for an alteration in liver function.
Although some significant changes were observed, none of the observed average data
points were overall extremely out of range for rats of this strain and age. Other biochemical
parameters and the blood cell counts showed no significant differences among the groups. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Increased weight gain in the high dose groups.
Increased liver and kidney weights in the male high dose group and increased liver weight in the female high dose group. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- behaviour (functional findings)
- body weight and weight gain
- clinical biochemistry
- clinical signs
- gross pathology
- haematology
- histopathology: neoplastic
- histopathology: non-neoplastic
- mortality
- neuropathology
- organ weights and organ / body weight ratios
- water consumption and compound intake
- Critical effects observed:
- no
- Conclusions:
- Detailed clinical signs, food consumption, motor activity, and reactivity to sensory stimuli
showed no abnormalities. On the last two days of the in-life phase, the male high dose
animals appeared apathetic.
Especially the female animals of the high dose group showed a significantly increased weight
gain in comparison to the vehicle groups. This effect was less pronounced in the other dose
groups. Water consumption was elevated in the test item groups of both sexes, particularly in
the high dose groups.
Of the hematology and serum biochemistry parameters, none were overall extremely out of
range for rats of this strain and age. In comparison to the vehicle groups, the animals of the
male high dose group showed lowered creatinine and GOT levels and elevated chloride and
cholesterol levels, as well as a higher mean corpuscular volume. The animals of the female
high dose group showed lowered creatinine and elevated globulin, chloride, GPT, and
alkaline phosphatase levels.
At necropsy, no treatment related changes were noted. The most noticable differences in
organ weights were an increased liver and kidney weight in the male high dose group and an
increased liver weight in the female high dose group.
Microscopically, there were no pathologic findings that are considered to be related to the
treatment with the test item.
The blood parameters, organ weights, and water consumption may point to an alteration of
liver and kidney function if the test item is administered at a high dose and over a longer
period of time, but under the conditions of this study, the repeated oral administration of the
test item Bromo(hexahydro-2H-azepin-2-onato-N)magnesium to Wistar-Unilever rats at dose
levels of 1.000, 250, and 63 mg/kg bodyweight for a treatment period of 28 days did not
produce any pathological evidence of a local or systemic toxicity of the test item. - Executive summary:
No evidence of a local or systemic toxicity of the test item was observed at levels of 1.000, 250, and 63 mg/kg bodyweight for a treatment period of 28 days.
The NOAEL was set to 1.000 mg/kg bw/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- satisfying
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
No indication for classification based on repeated dose toxicity tests for Bromo(hexahydro-2H-azepin-2-onato-N)magnesium.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.